The US is considering approving VTAMA cream, a treatment for skin conditions, for atopic dermatitis. Organon has bought Dermavant Sciences, enhancing its range of skin treatments. This acquisition includes VTAMA cream, already approved for treating plaque psoriasis. The US is reviewing VTAMA for use in treating atopic dermatitis in adults and children over two years old, with a decision expected by late 2024.
Organon agreed to pay up to $1.2 billion for Dermavant, including an initial $175 million and $75 million if the cream gets regulatory approval. They might also pay up to $950 million more based on sales success. Organon CEO Kevin Ali highlighted the importance of innovative treatments like VTAMA for skin conditions. Dermavant owns VTAMA globally, except in China and Japan.
Organon will take on Dermavant’s liabilities, valued at around $286 million. Legal and financial advice for the deal came from various firms.